Rhythm Pharmaceuticals Files 8-K

Ticker: RYTM · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1649904

Rhythm Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRhythm Pharmaceuticals, Inc. (RYTM)
Form Type8-K
Filed DateDec 11, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

Related Tickers: RYTM

TL;DR

RHYTHM PHARMACEUTICALS FILED AN 8-K ON DEC 11, 2025 - FINANCIAL STATEMENTS AND EXHIBITS.

AI Summary

On December 11, 2025, Rhythm Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates or disclosures related to the company's financial health and operations. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing indicates Rhythm Pharmaceuticals is providing updated financial information or exhibits to the SEC, which could be relevant for investors assessing the company's current financial standing.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative or positive events.

Key Players & Entities

  • RHYTHM PHARMACEUTICALS, INC. (company) — Registrant
  • December 11, 2025 (date) — Date of Report
  • 222 Berkeley Street 12th Floor Boston, MA 02116 (address) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing by Rhythm Pharmaceuticals?

The primary purpose of this 8-K filing is to report financial statements and exhibits as of December 11, 2025.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is December 11, 2025.

What is Rhythm Pharmaceuticals' principal executive office address?

Rhythm Pharmaceuticals' principal executive office is located at 222 Berkeley Street, 12th Floor, Boston, MA 02116.

What is the SEC file number for Rhythm Pharmaceuticals?

The SEC file number for Rhythm Pharmaceuticals is 001-38223.

What is the SIC code for Rhythm Pharmaceuticals?

The Standard Industrial Classification (SIC) code for Rhythm Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-12-11 07:50:13

Key Financial Figures

  • $0.001 — ange on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 11, 2025, Rhythm Pharmaceuticals, Inc. ("Rhythm") issued a press release and published a presentation announcing preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), which are summarized under Item 8.01 below. The presentation is available in the "Events and Presentations" portion of the Company's website at ir.rhythmtx.com. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly provided by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. On December 11, 2025, Rhythm announced preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS), which are summarized below. Rhythm enrolled 18 patients with PWS aged 6-65 years old with a BMI 30 kg/m2 for patients 18 years of age or BMI 95th percentile for age and sex for patients younger than 18. The 52-week trial remains ongoing. Setmelanotide therapy demonstrated potential therapeutic benefit with BMI and hyperphagia reductions in patients with PWS at Month 3 (n=8) and Month 6 (n=5); Highlights from preliminary results, as of a cut-off date of Nov. 14, include: Six (6) of 8 patients who reached Month 3 of setmelanotide therapy achieved BMI reductions from baseline; Three (3) of 5 patients who reached Month 6 of setmelanotide therapy achieved reductions in BMI, with two seeing deeper reductions versus Month 3 and one unchanged; Six (6) of 7 evaluable patients who reached Month 3 of setmelanotide therapy achieved meaningful reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scores; one patient's baseline and Month 3 HQ-CT score was 0, therefore not evaluable; Seventeen (17) of the 18 patients enrolled remain on active setmelanotide therapy; and Safety and tolerability results have been consistent with setmelanotide's well-established clinical profile.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits The following Exhibits 99.1 and 99.2 shall be deemed to be furnished and not filed. Exhibit No. Description 99.1 Press release dated December 11, 2025 99.2 Presentation dated December 11, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: December 11, 2025 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.